Biotech & MedTech News
-
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which…
-
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
February 6, 2024 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
FendX Technologies Announces Closing of Non-Brokered Private Placement with Strategic Investors and Upsizing
February 2, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
January 30, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences…
-
FendX to Conduct Third Pilot Run on Dunmore’s Commercial Manufacturing Line for Further Development of REPELWRAP(TM) Film
January 24, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
FendX Technologies to Present at The Microcap Conference in Atlantic City, New Jersey
January 23, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters
January 22, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company,…
-
Zentek Announces Eric Wallman Appointed as Chairman of the Board
January 19, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company,…
-
DIAGNOS Appoints New Chief Operating Officer
January 16, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX Technologies to Participate at Upcoming AlphaNorth Capital Event
January 12, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
